Pictured above: (l-r) Andrew Newell, Tim Powell, Ian
Mackenzie, Piyush Patel and Paul Markgraf
A pioneering invention developed in the Midlands is set to
become commonplace in the medical industry after receiving valuable
backing from an investment network.
Cipher Surgical, which is based at the University of Warwick
Science Park's Venture Centre on Sir William Lyons Road in
Coventry, has just secured investment bringing the total raised to
date to over £1million for the launch of a new medical
product called OpClear.
The revolutionary product has been developed to address a common
problem associated with cameras used during stomach surgery or the
surrounding abdominal region.
Andrew Newell, managing director of Cipher Surgical, said:
"During surgery the view of the small camera inserted into a
patient's stomach region often becomes obscured by blood and other
debris and previously the surgeon would be forced to remove the
camera to clear the obstruction.
"OpClear allows the surgeon to clear the view of the camera at
the end of the laparoscope without the need to remove it - this
reduces delays, lowering the time under anaesthesia making
operations quicker and safer.
Around £100,000 of the investment came from the University
of Warwick Science Park's Minerva Business Angel Network with a
further £125,000 from Midven, the West Midlands specialist
venture capital company, and Newell explained the importance of
this type of investment.
"Angel investment is vitally important to start-up
businesses like ours as other sources of funding are simply not
available anymore," he added.
"This investment will allow us to market the product to the
global medical industry and we hope to have it fully launched by
2014."
Cipher Surgical employs five people and moved to the University
of Warwick Science Park in January under the Ignite programme,
which is designed to support start-up and early stage companies by
allowing them to tap into the park's resources and knowledge
base.
In the last 12 months the Minerva Business Angel Network, which
aims to assist small and medium size businesses with high-growth
potential access the funding they need to fulfil their promise, has
completed nine investments raising in excess of £2 million
funding. Midven, which specialises in funding early stage and
growth companies, has co-invested in four of these investments from
its Early Advantage fund.
Tim Powell, who heads up Minerva, said: "We are delighted to
have been given the opportunity to support Andrew and his team as
we believe this product will have major appeal within the medical
industry.
"Like all good inventions, it is providing an effective solution
to a common problem and it ticked all the right boxes with the
investors."
Dr Andrew Muir, investment director at Midven, said "We expect
the OpClear to be launched initially in Europe in 2012 but this
product has a global market opportunity.
"We like the management team who have substantial experience in
this sector, augmented by the complementary skills of one of the
business angel investors who has joined the board."